Overview
- Perioperative Imfinzi paired with pre-surgery enfortumab vedotin, which AstraZeneca disclosed Thursday, improved event-free and overall survival versus surgery alone in muscle-invasive bladder cancer.
- A second regimen that also included Imjudo raised event-free survival but did not reach statistical significance for overall survival at this interim check.
- Safety matched the known profiles of the drugs with no new safety issues reported.
- VOLGA is a global Phase III study of 695 people that tested therapy before and after surgery across three groups against standard radical cystectomy.
- AstraZeneca plans to present full data and engage regulators next, a step that could change care for many patients who cannot take cisplatin due to kidney problems or other health issues.